No fast approval for immunotherapy combo in first line use.
Proactive and included patients can help clinical trial retention.
Merrimack sells off Onivyde and generic cancer drug
Companies to develop bispecific antibodies.
Gilead makes key hiring amid M&A rumours.
FDA concerned over potential liver toxicity.
Clovis’ Rubraca will compete against AstraZeneca rival.
pharmaphorum media and Symplur, LLC launch Conference360 Report to help pharma and other stakeholders understand social media conversations around medical congresses